Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors

BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors are used in a variety of malignancies. Infections have been reported with these drugs. We performed an up-to-date meta-analysis to further characterise the risk of infections in cancer patients treated with these agents. METHODS: Pubmed and...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kaymakcalan, M D, Je, Y, Sonpavde, G, Galsky, M, Nguyen, P L, Heng, D Y C, Richards, C J, Choueiri, T K
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2013
Teme:
Translational Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3694254/
https://ncbi.nlm.nih.gov/pubmed/23736025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.278
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items